MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer.
In addition, MannKind is applying our novel technologies and services to support partner development efforts. More >
Our lead investigational product candidate, AFREZZA®
Researchers announced the first successful clinical trial using the artificial pancreas in conjunction with ultra-rapid acting inhaled insulin (AFREZZA® ). To read the release and watch the video, click here: More >